The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).
1 Primary · 11 Secondary · Reporting Duration: Approximately 4 years
6000 Total Participants · 2 Treatment Groups
Primary Treatment: Olpasiran · Has Placebo Group · Phase 3
Age 18 - 85 · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: